Appointment of Cassandra Harrison to Vice President Clinical Operations and Data Management

Chimeric Therapeutics (ASX:CHM, “Chimeric”), a clinical-stage cell therapy company and an Australian leader in cell therapy, is pleased to announce that it has appointed Ms Cassandra Harrison to the position of Vice President (VP) Clinical Operations and Data Management.

Ms Harrison joins Chimeric with more than 10 years experience in clinical operations, compliance, and data management. Until recently, Ms Harrison was Vice President of Clinical Operations and Data Management at ImmunoGenesis, Inc., an immuno-oncology company, where she built both the clinical operations and data management departments and provided oversight on all aspects of data management and clinical operations.

Ms Harrison has extensive cell therapy experience from her previous role at Bellicum Pharmaceuticals where she was part of the pioneering team exploring CAR T cell therapies in solid tumours. At Bellicum she led, managed and implemented organisational resources, oversaw data management and outsourcing across multiple clinical programs.

Ms Harrison holds active nursing licensures in North Carolina, Massachusetts, and Pennsylvania. She also has a Master of Business Administration from Apsen University, Colorado, and a Master of Public Health from Walden University, Minnesota.

This VP Clinical Operations role will focus on leading Chimeric’s successful execution of all clinical program operations as it moves forward with a portfolio of four phase 1 clinical trials. Chimeric recently established a A$30 million equity funding agreement with leading global investor, L1 Capital Global Opportunities Master Fund which will be used to progress the clinical pipeline.

Chimeric’s CEO & Managing Director Jennifer Chow said “We are excited to welcome Cassandra as the Vice President Clinical Operations at Chimeric, a newly created but critically important position within our organisation. She is a high calibre addition to our management team who will play a key role in advancing our clinical pipeline at this exciting and pivotal time for the business.”